In this paper, we have identified RNF19A as a novel onco‐driver in NSCLC based on two observations: (1) RNF19A was highly expressed in NSCLC tissues, and its overexpression was positively correlated with poor patient outcome in NSCLC; (2) RNF19A increased NSCLC cell proliferation and survival. This evidence concerns the gene RNF19A and non-small cell lung carcinoma.